Free tool
FAERS Monitor: Ohtuvayre
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217389 or its brand name (Ohtuvayre, Ensifentrine). Reports on generic versions are filed under their own applications.
Reports
1,830
Serious
635
35% of reports
Hospitalization
343
Death reported
73
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea376
- drug ineffective132
- chronic obstructive pulmonary disease129
- diarrhoea106
- cough99
- back pain98
- pneumonia94
- product dose omission issue91
- no adverse event83
- death82
- headache75
- chest discomfort63
- incorrect dose administered59
- productive cough55
- fatigue54
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 27 |
| 2025 | 783 |
| 2026 | 1,008 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,329 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic obstructive pulmonary diseaseSignal | 129 | 28.5 | 24.1 | 3,393 |
| productive coughSignal | 55 | 13.3 | 10.2 | 612 |
| dyspnoeaSignal | 376 | 7.6 | 7.0 | 2,221 |
| chest discomfortSignal | 63 | 7.1 | 5.5 | 324 |
| no adverse eventSignal | 83 | 5.3 | 4.3 | 285 |
| back painSignal | 98 | 4.8 | 4.0 | 299 |
| coughSignal | 99 | 4.1 | 3.4 | 228 |
| product dose omission issueSignal | 91 | 3.6 | 2.9 | 167 |
| pneumoniaSignal | 94 | 3.3 | 2.7 | 154 |
| incorrect dose administeredSignal | 59 | 3.0 | 2.3 | 76 |
| diarrhoea | 106 | 1.9 | 1.6 | 45 |
| headache | 75 | 1.4 | 1.1 | 8 |
| drug ineffective | 132 | 1.2 | 1.0 | 3 |
| death | 82 | 1.1 | 0.9 | 1 |
| fatigue | 54 | 0.8 | 0.6 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.